Market Overview

Glaxo, Theravance Confirm BREO ELLIPTA Gained US FDA Approval for Treatment of COPD

Related GSK
EXCLUSIVE: FBB's Mike Bailey On Pfizer-Allergan Deal, Taxes, Rate Hike And Biotech Picks
Idera to Collaborate With GSK to Identify 3rd Generation Antisense Molecules for Treatment of Renal Disease
Ad Comm approaches for Fabre-Kramer's MDD med (Seeking Alpha)
Related THRX
Glaxosmithkline, Theravance Intend to File Relvar Ellipta for COPD in Japan
Theravance Just Lost Its Catalyst

GlaxoSmithKline plc (NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that the US Food and Drug Administration (FDA) has approved BREO(TM) ELLIPTA(TM) as an inhaled long-term, once-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. It is also indicated to reduce exacerbations of COPD in patients with a history of exacerbations. BREO ELLIPTA is a combination of the inhaled corticosteroid (ICS), fluticasone furoate "FF", and the long-acting beta2 agonist (LABA), vilanterol "VI" (FF/VI 100/25 mcg).

Posted-In: News FDA


Related Articles (THRX + GSK)

View Comments and Join the Discussion!

Get Benzinga's Newsletters